ALDX Aldeyra Therapeutics Inc.

5.66
+0.51  (+10%)
Previous Close 5.15
Open 5.19
Price To Book 2.32
Market Cap 156,092,878
Shares 27,578,247
Volume 214,357
Short Ratio
Av. Daily Volume 205,456
Stock charts supplied by TradingView

NewsSee all news

  1. Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present on Thursday, October 10 at the Ophthalmology Innovation Summit (OIS) at the

  2. Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company's ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic

  3. Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 (Part 1) to be completed 4Q 2019.
ADX-102 - topical ocular reproxalap - RENEW
Dry eye syndrome
Phase 3 data March 25, 2019 - primary endpoint met.
Reproxalap (ADX-102)
Allergic conjunctivitis
Phase 3 data did not meet endpoints - June 25, 2019.
ADX-102 reproxalap
Noninfectious anterior uveitis
Phase 3 Part 1 section of trial completed.
Reproxalap (ADX-102)
Sjögren-Larsson Syndrome (SLS)
Phase 2 trial to be initiated 2H 2019.
ADX-1612 (ganetespib)
Post-transplant lymphoproliferative disorder
Phase 3 trial to be initiated 2H 2019 with initial data due 2020.
ADX-2191
Proliferative vitreoretinopathy (PVR)
Phase 3 trial to be initiated 4Q 2019 with initial data due 2020.
ADX-2191
Proliferative vitreoretinopathy (PVR)

Latest News

  1. Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present on Thursday, October 10 at the Ophthalmology Innovation Summit (OIS) at the

  2. Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company's ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic

  3. Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today